公开(公告)号：US10138232B2

公开(公告)日：2018-11-27

申请号：US14728613

申请日：2015-06-02

Applicant: NOVARTIS AG

Inventor： Juergen Reinhardt ,  Niko Schmiedeberg ,  Carsten Spanka

IPC: C07D471/04 ,  A61K31/4375 ,  C07D471/16 ,  A61K31/444 ,  A61K31/4745 ,  C07D471/14 ,  C07D495/14 ,  A61K45/06

Abstract: The invention relates to compound of the formula (I′) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.

公开(公告)号：US20240199593A1

公开(公告)日：2024-06-20

申请号：US18426461

申请日：2024-01-30

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form;

a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11932630B2

公开(公告)日：2024-03-19

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian Xie

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220348566A1

公开(公告)日：2022-11-03

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/14 ,  C07D471/04 ,  A61K31/436 ,  C07D401/14 ,  C07D401/12 ,  C07D257/04 ,  A61K31/41

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US09884862B2

公开(公告)日：2018-02-06

申请号：US15315579

申请日：2015-06-02

Applicant: Novartis AG

Inventor： Niko Schmiedeberg ,  Carsten Spanka

IPC: C07D471/04 ,  C07D495/14 ,  A61K45/06 ,  A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K45/06 ,  C07D495/14 ,  A61K2300/00

Abstract: The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.